Latest From Catalent Inc.
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.
Mega-merger's top US drug candidates are seeking space in crowded fields. That means they have to get through the FDA fast, and priority review vouchers figure prominently in both improving and lowering the odds.
An FDA warning letter issued to Aurobindo highlights recurring failures over several sites, while Teva is setting up a biologics development campus in the US and Nexus is investing in sterile injectables capacity.
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
- Synthesis Technologies, Production Processes
- Contract Research, Toxicology Testing-CRO
- Controlled Release
- OTC, Consumer
- Drug Delivery
- Therapeutic Areas
- Cardinal Health PTS
- Catalent Inc.
- Catalent Pharma Solutions Inc.
- North America
- Parent & Subsidiaries
- Catalent Inc.
- Senior Management
John Chiminski, Chmn. & CEO
Wetteny Joseph, SVP, CFO
Scott Gunther, SVP, Quality & Reg. Affairs
Alessandro Maselli, Pres. & COO
Karen Flynn, Chief Commercial Officer
- Contact Info
Phone: (732) 537-6200
14 Schoolhouse Rd.
Somerset, NJ 08873
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.